Kadcyla was one of the most expensive drugs on the CDF, costing up to £65,000 per patients, and charity Breast Cancer Now took the unusual step of calling on Roche to lower its price.

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial.

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE. The row over Kadcyla has lasted three years, and has been one of ...

Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

Metastatic breast cancer, also known as stage 4 breast cancer ... trastuzumab emtansine (Kadcyla) Side effects may include diarrhea, hair loss, nausea, fatigue, and a rash on your skin.

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 ...

(Updates with additional information on the type of breast cancer Kadcyla is approved to treat starting in the second paragraph.) WASHINGTON--The U.S. Food and Drug Administration Friday approved ...

The company has shown that the amanitin-based drugs kill cancer cells that are resistant to other treatments, including HER2-positive breast cancer ... conjugates such as Kadcyla (trastuzumab ...